RxDoctor Payments Data

Jeffrey Harter

Optometrist · Raytown, MONPI 1831326339

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 92.2% of the total across 113 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Alcon at 25.5% of the total.

$3,208in general payments, 2019–2025

Across 113 payments — averaging $28.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$817
  • Coopervision Inc.$482
  • Johnson & Johnson Vision Care, Inc.$359
  • Mallinckrodt Hospital Products Inc.$221
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$195
  • Novartis$188
  • plus $946 from 14 others
$112,480in research payments, 2019–2025

Across 8 payments — averaging $14,060 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Johnson & Johnson Vision Care, Inc.$112K

What the payments were for

  • Speaking & faculty fees$2508%
  • Food & beverage$2,95892%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,208 in reported general payments places this provider in the 85th percentile of 1,030 optometrist providers in Missouri.

See all optometrist providers in Missouri

Medicare billing

Part B allowed, 2024
$27,782
Medicare patients
177
Services billed
330

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast23$35,369
RestasisCyclosporine15$15,035
VyzultaLatanoprostene Bunod12$4,984
Latanoprost140$1,693
Timolol Maleate22$100

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$99$40,35335 claims
AbbVieRestasis$95$15,03515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,030 optometrist providers in Missouri.

Other optometrist in Raytown

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →